Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

261 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.
Alvarez-Larrán A, Garrote M, Ferrer-Marín F, Pérez-Encinas M, Mata-Vazquez MI, Bellosillo B, Arellano-Rodrigo E, Gómez M, García R, García-Gutiérrez V, Gasior M, Cuevas B, Angona A, Gómez-Casares MT, Martínez CM, Magro E, Ayala R, Del Orbe-Barreto R, Pérez-López R, Fox ML, Raya JM, Guerrero L, García-Hernández C, Caballero G, Murillo I, Xicoy B, Ramírez MJ, Carreño-Tarragona G, Hernández-Boluda JC, Pereira A; MPN Spanish Group (Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas). Alvarez-Larrán A, et al. Among authors: bellosillo b. Cancer. 2022 Jul 1;128(13):2441-2448. doi: 10.1002/cncr.34195. Epub 2022 Apr 13. Cancer. 2022. PMID: 35417564 Free PMC article.
Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients.
Alvarez-Larrán A, Cervantes F, Bellosillo B, Giralt M, Juliá A, Hernández-Boluda JC, Bosch A, Hernández-Nieto L, Clapés V, Burgaleta C, Salvador C, Arellano-Rodrigo E, Colomer D, Besses C. Alvarez-Larrán A, et al. Among authors: bellosillo b. Leukemia. 2007 Jun;21(6):1218-23. doi: 10.1038/sj.leu.2404693. Epub 2007 Apr 12. Leukemia. 2007. PMID: 17519959
JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis.
Martínez-Avilés L, Besses C, Alvarez-Larrán A, Cervantes F, Hernández-Boluda JC, Bellosillo B. Martínez-Avilés L, et al. Among authors: bellosillo b. Haematologica. 2007 Dec;92(12):1717-8. doi: 10.3324/haematol.12011. Haematologica. 2007. PMID: 18056003 Free article.
Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden.
Arellano-Rodrigo E, Alvarez-Larrán A, Reverter JC, Colomer D, Villamor N, Bellosillo B, Cervantes F. Arellano-Rodrigo E, et al. Among authors: bellosillo b. Am J Hematol. 2009 Feb;84(2):102-8. doi: 10.1002/ajh.21338. Am J Hematol. 2009. PMID: 19105233 Free article.
Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia.
Alvarez-Larrán A, Cervantes F, Pereira A, Arellano-Rodrigo E, Pérez-Andreu V, Hernández-Boluda JC, Ayats R, Salvador C, Muntañola A, Bellosillo B, Vicente V, Hernández-Nieto L, Burgaleta C, Xicoy B, Besses C. Alvarez-Larrán A, et al. Among authors: bellosillo b. Blood. 2010 Aug 26;116(8):1205-10; quiz 1387. doi: 10.1182/blood-2010-01-263319. Epub 2010 May 27. Blood. 2010. PMID: 20508163 Free article.
Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia.
Hernández-Boluda JC, Alvarez-Larrán A, Gómez M, Angona A, Amat P, Bellosillo B, Martínez-Avilés L, Navarro B, Teruel A, Martínez-Ruiz F, Besses C. Hernández-Boluda JC, et al. Among authors: bellosillo b. Br J Haematol. 2011 Jan;152(1):81-8. doi: 10.1111/j.1365-2141.2010.08430.x. Epub 2010 Nov 18. Br J Haematol. 2011. PMID: 21083657 Free article.
Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia.
Maffioli M, Camós M, Gaya A, Hernández-Boluda JC, Alvarez-Larrán A, Domingo A, Granell M, Guillem V, Vallansot R, Costa D, Bellosillo B, Colomer D, Cervantes F. Maffioli M, et al. Among authors: bellosillo b. Leuk Res. 2011 Aug;35(8):1014-9. doi: 10.1016/j.leukres.2010.12.004. Epub 2010 Dec 24. Leuk Res. 2011. PMID: 21185600
261 results